Key Takeaways AstraZeneca's anselamimab missed the primary endpoint in both phase III CARES studies for AL amyloidosis. The drug showed a clinically meaningful benefit in a prespecified subgroup, but details remain undisclosed. AZN plans a full analysis of the data and will present findings at an upcoming medical meeting.AstraZeneca (AZN) reported disappointing results from two late-stage studies that evaluated its investigational light chain depleter antibody, anselamimab, in certain patients with a rare ...